Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Zhaohui Gu(City of Hope), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Issa F. Khouri(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Yuya Sasaki(The University of Texas MD Anderson Cancer Center), Guillaume Richard‐Carpentier(The University of Texas MD Anderson Cancer Center), Kathryn G. Roberts(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Heather Schroeder(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Feng Wang(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(Unknown), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Sa Wang(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Maria Khouri(The University of Texas MD Anderson Cancer Center)
Cited by 64
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k